Leerink Partners Upgrades Johnson & Johnson to Outperform, Announces $265 Price Target
Johnson & Johnson
Johnson & Johnson JNJ | 0.00 |
Leerink Partners analyst David Risinger upgrades Johnson & Johnson (NYSE:
JNJ) from Market Perform to Outperform and announces $265 price target.
